These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28480956)

  • 21. SGLT2 inhibitors and renal function.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
    [No Abstract]   [Full Text] [Related]  

  • 22. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.
    Riggs K; Ali H; Taegtmeyer H; Gutierrez AD
    Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(3):409-18. PubMed ID: 26732230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors.
    Dardi I; Kouvatsos T; Jabbour SA
    Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
    Abdul-Ghani MA; Norton L; DeFronzo RA
    Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP; Cuthbertson DJ; Wilding JP
    Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 40. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
    Machado UF; Corrêa-Giannella ML
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.